Core Viewpoint - The article highlights the significant advancement of Goli Pharma in the development of ASC37, a next-generation GLP-1R/GIPR/GCGR tri-agonist peptide, which is set to enter clinical trials for obesity treatment in 2026, marking a key milestone in multi-target metabolic drug development [4][6]. Group 1: Drug Development and Characteristics - ASC37 has been developed using Goli's AI-assisted drug discovery platform and ultra-long-acting drug development platform, showing enhanced agonistic activity at GLP-1R, GIPR, and GCGR receptors, approximately 5 times, 4 times, and 4 times stronger than the leading candidate retatrutide, respectively [6]. - The drug's design allows for a significant extension of its apparent half-life, supporting monthly subcutaneous administration with a single injection volume of less than 1 mL, which is expected to improve patient compliance and reduce manufacturing costs [6][7]. - In non-human primate studies, ASC37 demonstrated an average apparent half-life of about 17 days, which is 7 times longer than that of retatrutide, indicating superior in vivo exposure maintenance capabilities [7]. Group 2: Therapeutic Applications and Combination Strategies - ASC37 is being developed for single-agent and combination therapies targeting obesity, diabetes, and metabolic dysfunction-related fatty liver disease (MASH), addressing high-burden chronic diseases [7]. - Goli plans to explore the synergistic effects of ASC37 in combination with another monthly subcutaneous amylin receptor agonist peptide, ASC36, aligning with the global trend of integrating multiple pathways in metabolic drug development [7]. Group 3: Technological Platforms and Industry Position - The AISBDD and ULAP platforms are foundational to Goli's continuous output of peptide pipelines, allowing for the design of various release rates for subcutaneous depot peptides, achieving a better balance between efficacy, safety, and patient experience [8]. - The advancement of ASC37 reflects the shift of Chinese innovative pharmaceutical companies from imitation to competitive participation in global markets, particularly in drug frequency, pharmacokinetics, and system engineering [8].